BioTime Presents Retinal Restoration Data at ARVO
Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue
Tissue is Highly Similar to Natural Human Tissue
ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that a poster related to the Company’s retinal
restoration technology was presented at the Annual
Meeting of the Association for Research in Vision and Ophthalmology
(ARVO) in Baltimore, Maryland on May 11, 2017.
BioTime scientists have grown full-thickness, 3-D retinal tissue using
the Company’s proprietary pluripotent cellular platform. This tissue
contains all the cell types that comprise the human retina, including
RPE cells, photoreceptors and ganglion cells. Data presented at ARVO
demonstrates that BioTime’s 3-D retinal tissue closely resembles young,
natural human retinal tissue. The technology may ultimately be used to
repair and restore sections of degenerated retinal tissue and possibly
help restore visual function, irrespective of the condition that caused
vision loss or blindness. Study authors conclude the Company’s 3-D
retinal tissue may address the limiting factor of implementing a retinal
restoration strategy to address severe retinal degenerative diseases,
the availability of mutation-free retinal tissue.
“We are building a pipeline of ophthalmic therapeutics that can be
efficiently manufactured in a lab,” stated Adi Mohanty, Co-Chief
Executive Officer. “We are combining our regenerative medicine expertise
and our pluripotent cell technology platform with current ophthalmic
transplant techniques to develop therapeutics that address many
degenerative diseases of the eye.”
More information about the 3-D retinal tissue study is available here.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime
founded and which, until recently, were majority-owned consolidated
subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
View source version on businesswire.com: http://www.businesswire.com/news/home/20170511005464/en/
Source: BioTime, Inc.
EVC Group, Inc.
Brian Moore, 310-770-0389
JQA Partners, Inc.
Jules Abraham, 917-885-7378